CEVEC closes major financing round to further expand and commercialize its viral vector manufacturing platform

  • Funding strengthens CEVEC’s leading role in viral vector manufacturing technology
  • CEVEC’s technology allows for industrial scale manufacturing of AAV vectors and opens the field for gene therapy applications in a wide range of indications

Cologne, Germany, April 16, 2019

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the successful closing of a Series D financing round with new and existing investors. The funding will be allocated to the expansion and commercialization of CEVEC’s CAP®GT-based stable adeno-associated viral (AAV) vector production platform and to the broadening of the Company’s technology portfolio.